Cell Culture Medium Composition for Immune Cell Expansion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cell culture media for immune effector cells and hematopoietic stem/progenitor cells do not adequately support proliferation, viability, and maintenance of cellular phenotypes, leading to suboptimal therapeutic outcomes and high manufacturing costs.
Innovation Solution
A culture medium with controlled osmolarity (275-320 mOsm/kg) and L-ornithine supplementation, along with recombinant growth factors like IL-2, is used to enhance cell proliferation, viability, and therapeutic protein expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current commercially available cell culture media are used, then manufacturing process is simple and cost-effective, but cell proliferation, viability, and therapeutic protein expression are insufficient
Solution Approach 1:
The patent optimizes specific parameters of the culture media including osmolarity (275-320 mOsm/kg), pH (7.0-7.4), and temperature (37°C), along with precise concentrations of amino acids, vitamins, and growth factors, to achieve enhanced cell proliferation while maintaining manageable manufacturing complexity
Solution Approach 2:
The patent employs a composite media formulation combining multiple components including base media (RPMI-1640 or DMEM), amino acids (L-glutamine, L-alanine, L-ornithine), vitamins, growth factors (IL-2, EPO), and serum replacements, where each component contributes specific functions to achieve synergistic effects for improved cell growth and therapeutic protein expression
2Reliability
If current cell culture media are used, then manufacturing costs are reduced, but cell viability and therapeutic potency decrease
Solution Approach 1:
The patent specifies precise parameter ranges including osmolarity (275-320 mOsm/kg), pH (7.0-7.4), and temperature (37°C) to optimize cell viability, while the defined composition allows for cost-effective manufacturing through standardized production of individual components
Solution Approach 2:
The optimized media formulation enables cells to maintain high viability and therapeutic potency through self-regulating mechanisms supported by the balanced composition of nutrients and growth factors, reducing the need for frequent media changes and intensive monitoring, thereby lowering overall manufacturing costs
3Productivity
If current cell culture media are used, then manufacturing process is straightforward, but cell proliferation and expansion efficiency are low
Solution Approach 1:
The patent divides the complex media formulation into separate preparable components including base media, amino acid solutions, vitamin mixes, and growth factor additions, allowing each component to be prepared and quality-tested independently before final assembly, thus maintaining manufacturing simplicity while achieving high cell expansion efficiency
Solution Approach 2:
The patent defines specific parameter ranges for osmolarity (275-320 mOsm/kg), pH (7.0-7.4), and component concentrations that optimize cell proliferation rates, enabling straightforward manufacturing processes that consistently produce high-yield cell expansions
4Quantity of substance
If current cell culture media are used, then manufacturing time is short, but therapeutic protein expression and cell potency are insufficient
Solution Approach 1:
The patent incorporates pre-optimized concentrations of amino acids (particularly L-ornithine at 0.1-5.0 mM), vitamins, and growth factors (IL-2 at 10-1000 IU/mL, EPO at 1-100 IU/mL) in the media formulation before cell culture initiation, enabling cells to immediately begin high-level therapeutic protein expression without requiring extended adaptation periods, thus achieving high potency within compressed manufacturing timelines
Data Source
AI summary
The present disclosure provides improved cell culture media for maintaining and expanding immune effector cell and hematopoietic stem or progenitor cell populations.